REMEGEN (688331.SH) announces a forecasted net loss of approximately 1.47 billion yuan for 2024.

REMEGEN (688331.SH) announced that the company expects to achieve a net loss attributable to the owners of the parent company of approximately 1.47 billion yuan in 2024, a decrease of about 41 million yuan compared to the same period last year, with a year-on-year decrease of about 3%. The company's new drug R&D pipeline has continued to advance this year, with several innovative drugs in key trial stages. R&D investment has increased, and sales revenue of Tabocta and Vedixustat monoclonal antibodies have grown rapidly. The gross profit margin of the products continues to increase, and the sales expense ratio has significantly decreased. Therefore, it is expected that the company will have a decreasing trend in net loss for 2024, showing a decreasing loss trend both before and after deducting non-recurring gains and losses.